This webcast features: Claire Tardy, PhD, Research & Development Manager, Capsule Delivery Solutions, Lonza Pharma & Biotech

Dry-powder inhalation (DPI) is a major drug delivery technology for the treatment of respiratory diseases and increasingly for systemic drug delivery. Providing a uniform dose in a portable, easy-to-use system, capsule-based DPI is a simple and cost-effective way to deliver medication via the pulmonary route.

Within dry-powder inhalation application fields, Lonza offers the Capsugel® Zephyr™ Dry-Powder Inhalation portfolio: high-quality capsule solutions based on different polymers, tailored to enable consistent and optimal release performance. Polymer science and engineering have opened a new era of functional development, which offers the potential for selecting the right capsule for different APIs and different inhalation devices associated with a wider range of services.

Building on a history of innovation in polymer science and capsule engineering, the Capsugel® brand, now part of Lonza, offers a suite of HPMC and other polymer capsules for the pharmaceutical world. In this webinar, learn more about the Capsugel® Zephyr™ Dry-Powder Inhalation capsule portfolio.

Watch the recorded webcast below.